Gemigliptin/angiotensin receptor antagonistAlternative Names: ZemiARB
Latest Information Update: 20 May 2016
At a glance
- Originator LG Life Sciences
- Class Piperidines; Pyrimidines
- Mechanism of Action Angiotensin receptor antagonists; CD26 antigen inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- No development reported Hypertension; Type 2 diabetes mellitus